



Syndax Announces Participation in Cowen 2nd Annual Virtual Oncology Innovation Summit

May 13, 2021

WALTHAM, Mass., May 13, 2021 /PRNewswire/ -- Syndax Pharmaceuticals, Inc. ("Syndax," the "Company" or "we") (Nasdaq: SNDX), a clinical stage biopharmaceutical company developing an innovative pipeline of cancer therapies, today announced that members of its management team will participate in the Cowen 2nd Annual Virtual Oncology Innovation Summit on Thursday, May 20, 2021 at 12:00 p.m. ET.

A live webcast of the presentation can be accessed from the Investor section of the Company's website at www.syndax.com, where a replay of the event will also be available for a limited time.

About Syndax Pharmaceuticals, Inc.

Syndax Pharmaceuticals is a clinical stage biopharmaceutical company developing an innovative pipeline of cancer therapies. The Company's pipeline includes SNDX-5613, a highly selective inhibitor of the Menin-MLL binding interaction, axatilimab, a monoclonal antibody that blocks the colony stimulating factor 1 (CSF-1) receptor, and entinostat, a class I HDAC inhibitor. For more information, please visit www.syndax.com or follow the Company on [Twitter](#) and [LinkedIn](#).

Syndax Contacts

Investor Contact
Melissa Forst
Argot Partners
melissa@argotpartners.com
Tel 212.600.1902

Media Contact
Ted Held
ted_held@gcihealth.com
Tel 212.798.9842

SNDX-G

 View original content: <http://www.prnewswire.com/news-releases/syndax-announces-participation-in-cowen-2nd-annual-virtual-oncology-innovation-summit-301290613.html>

SOURCE Syndax Pharmaceuticals, Inc.